HIV therapy in an ageing population — the challenge of polypharmacy

Dj Back

doi:10.1186/1758-2652-13-s4-o26

Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

Highlights

Pharmacokinetic drug interaction studies performed during the drug development process, or post-licensing provide the substantive data base from which recommendations regarding the use of certain drug combinations are made
We need to appreciate that with the ageing process drug absorption and clearance can alter so the challenge is to understand how this may impact on the magnitude of a drug-drug interaction
While the major focus in the HIV field has been on CYP450 enzymes there is a growing awareness of the key role for other proteins - in particular UDP-glucuronyltransferases (UGTs) and transporters (ABC transporters such as Pgp, MRPs; SLCO transporters such as OATP1B1, OCTs, OATs)

Summary

Introduction

Pharmacokinetic drug interaction studies performed during the drug development process, or post-licensing provide the substantive data base from which recommendations regarding the use of certain drug combinations are made. HIV therapy in an ageing population — the challenge of polypharmacy From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK.

Results

Conclusion